Dicot's rights issue is registered - paid subscription units (BTU) are converted to shares and warrants, and trading of warrants commences

Uppsala, November 22, 2021. Dicot AB (publ) ("Dicot" or the "Company") has carried out a rights issue of units to an amount of approximately MSEK 25.3 ("the Rights Issue"). The Rights Issue was completed on October 27, 2021. The Rights Issue was subscribed to 97.9 percent. Through the Rights Issue, the Company obtains approximately MSEK 24.7 before issue costs.

The Rights Issue is now registered with the Swedish Companies Registration Office. The last day of trading in paid subscription units (BTU) is November 24, 2021. The record date is November 26, 2021; after this day, BTU will be converted to shares and warrants. The newly issued shares and warrants are expected to be delivered to the shareholders' securities deposit/vp-accounts on November 30, 2021. Trading of warrants of series 2021/2022 on Spotlight Stock Market will commence on November 30, 2021.

Through the Rights Issue, Dicot's share capital will increase by SEK 4,758,557.625 through the issuance of 38,068,461 shares. Following the registration of the Rights Issue with the Swedish Companies Registration Office, the Company's share capital amounts to SEK 12,862,525.745 and the total number of shares in the Company amounts to 102,900,206 shares.


Through the Rights Issue, the Company also issues 38,068,461 warrants of series 2021/2022, which entitle to subscribe for 38,068,461 shares in the Company.

The warrants of series 2021/2022 that have been issued through the Rights Issue entitle the holder to subscribe for one (1) new share in Dicot during the subscription period from June 1, 2022 through June 15, 2022. The subscription price for shares using the warrants will correspond to 70 percent of the volume weighted average price of the Company's shares according to the Spotlight Stock Market official price list for the period from May 16, 2022 through May 27, 2022 but will not be higher than SEK 1.50 or less than SEK 0.125 (corresponding to the quota value of the Company's shares).

Upon full exercise of all warrants of series 2021/2022 within the framework of issued units, the Company may receive up to an additional MSEK 57.1, depending on the exercise price. Upon full exercise of all warrants of series 2021/2022, the share capital will increase by an additional SEK 4,758,557.625.


Stockholm Corporate Finance AB is acting as financial adviser to the Company in the Rights Issue. Advokatfirman Lindahl KB is acting as the legal adviser to the Company. Hagberg & Aneborn Fondkommission AB is the issuing agent in the Rights Issue.

For further information, please contact:

Göran Beijer CEO
Tel: +46 706 63 60 09
Email: [email protected]

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 2,250 shareholders. For more information, please visit www.dicot.se.

Important information

This press release is not an offer to subscribe for shares, warrants, or units in Dicot and investors should not subscribe or acquire any securities. Invitation to concerned persons to subscribe for shares in Dicot will only be made through the EU growth prospectus that Dicot has published on its website on October 8, 2021 (as well as the supplement prospectus that Dicot has published on its website on October 20, 2021).

Neither unit rights, units subscribed for ("BTU") or newly issued units have been recommended or approved by any US federal or state securities authority or regulatory authority. No subscription rights, BTA or newly issued shares have been registered or will be registered under the United States Securities Act of 1933, as applicable, or in accordance with applicable laws in the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or in any other country where the Rights Issue or distribution of the press release is in violation of applicable laws or regulations or presupposes that a further investment memorandum is established, registered or that any other measure is undertaken beyond that required by Swedish law. Hence, this press release shall not, directly or indirectly, be released, published or distributed in or to the United States, Australia Japan, Canada, New Zealand, Hong Kong, South Africa or other country where such action as a whole or in part is subject to legal restrictions.

There is no intention to apply for approval of any offer to the public in any other country within the European Economic Area ("EES") than Sweden and the securities issued in the Rights Issue will not be offered to the public in these countries.

This press release may contain certain forward-looking information that reflects Dicot's current views on future events as well as financial and operational development. Words that are "intended", "come", "judged", "expected", "can", "plan", "appreciate" and other expressions that imply indications or predictions about future developments or trends, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties because it depends on future events and circumstances. Forward-looking information does not constitute a guarantee of future performance or development and actual outcomes may differ substantially from what is stated in forward-looking information. This information, the opinions and the forward-looking statements contained in this press release are valid only on this date and may be amended without notice. Dicot makes no representations about publishing updates or revisions of forward-looking information, future events or similar circumstances other than the applicable law.

Nerladdningsbara filer

Dicot AB Delårsrapport januari - mars 2022

Pressmeddelande: Uppsala, 6 maj 2022. Dicot ABs (publ) delårsrapport för januari - mars 2022 finns nu tillgänglig på bolagets hemsida www.dicot.se.

Finansiell information första kvartalet 2022

  • Nettoomsättningen uppgick till 0 kSEK (0)
  • Resultatet efter finansiella poster uppgick till -9 346 kSEK (-8 468)
  • Resultat per aktie uppgick till -0,09 SEK (-0,19)

Summary of Interim Report January - March 2022, Dicot AB

Press release: Uppsala, May 6, 2022. A summary of the Interim report January - March 2022, for Dicot AB (publ) is now available on the company website www.dicot.se 

First quarter 2022

  • Net sales amounts to kSEK 0 (0)
  • Earnings for the period amounts to kSEK -9,346 (-8,468)
  • Earnings per share SEK -0.09 (-0.19)

Dicots vd presenterar på Naventus Healthcare Summit 10 maj

Pressmeddelande: Uppsala, 5 maj 2022. Tisdag den 10 maj står Dicots vd Elin Trampe i Spegelsalen på Grand Hôtel i Stockholm och presenterar bolagets nuläge och framtid. Det sker klockan 14:25 under Naventus Healthcare Summit, ett evenemang som arrangeras av Naventus ihop med Setterwalls, Deloitte, Nordnet och Nasdaq.

Dicot's CEO to present at Naventus Healthcare Summit on May 10

Press release: Uppsala, May 5, 2022. On Tuesday May 10 at 14:25, Dicot's CEO Elin Trampe will present the company at the Naventus Healthcare Summit, an event organized by Naventus together with Setterwalls, Deloitte, Nordnet and Nasdaq.

Dicot till Aktiedagen på Operan i Stockholm

Pressmeddelande: Uppsala, 29 april 2022. På måndag den 2 maj står vd Elin Trampe på Operaterrassens scen och presenterar Dicot under Aktiespararnas event Aktiedagen Stockholm.

Dicot gör en kompletterande kommentar till revisionsberättelsen 2021

Pressmeddelande: Uppsala, 26 april 2022. Dicot AB (publ) offentliggjorde idag bolagets årsredovisning för 2021. Utifrån rekommendation från Spotlight kompletterar bolaget härmed tidigare pressmeddelande med information gällande revisorns särskilda upplysning i revisionsberättelsen.


Aktieägarna i Dicot AB (publ), org.nr 559006-3490 ("Bolaget"), kallas härmed till årsstämma tisdagen den 24 maj 2022 klockan 10.00 i Advokatfirman Lindahls lokaler på Vaksalagatan 10 i Uppsala.

Dr Charlotta Gauffin ny Chief Scientific Officer på Dicot

Pressmeddelande: Uppsala, 19 april 2022. Dr Charlotta Gauffin anställs 11 juli som Chief Scientific Officer på Dicot med uppdraget att leda utvecklingen av företagets potensläkemedel. Dr Gauffin har över 20 års erfarenhet av läkemedelsutveckling varav mer än 15 år inom klinisk utveckling.

Charlotta Gauffin PhD is the new Chief Scientific Officer at Dicot

Press release: Uppsala, April 19, 2022. Charlotta Gauffin PhD has been hired as Chief Scientific Officer at Dicot starting July 11 with the task of leading the development of the company's potency drug. Dr. Gauffin has over 20 years of experience in drug development, of which more than 15 years in clinical development.

Dicots valberedning föreslår Fredrik Buch och Michael Zell till nya styrelseledamöter

Pressmeddelande: Uppsala, 7 april 2022. Valberedningen i Dicot AB föreslår att Fredrik Buch och Michael Zell väljs till nya ordinarie styrelseledamöter i styrelsen för Dicot AB vid årsstämman 24 maj.

Dicot's nomination committee proposes Fredrik Buch and Michael Zell as new Board members

Press release: Uppsala, April 7, 2022. The Nomination Committee of Dicot AB proposes that Fredrik Buch and Michael Zell are elected as new ordinary Board members of the Board of Dicot AB at the Annual General Meeting on May 24.

Dicot vidareutvecklar LIB-01 till ett oralt läkemedel

Pressmeddelande: Uppsala, 6 april 2022. Dicot meddelar att man efter utvärdering av två formuleringsalternativ nu väljer att prioritera utvecklingen av en oral läkemedelskandidat inför fas 1-studie. Detta gör att tidplanen för start av första studie i människa revideras till mitten av 2023. Ett oralt läkemedel är enklare för patienter och innebär att Dicots läkemedelskandidat därmed kommer värderas högre i kommande affärsförhandlingar med potentiella partners.

Dicot to develop LIB-01 to an oral drug

Press release: Uppsala, April 6, 2022. Dicot announces that after evaluating two formulation alternatives, the company decides to prioritize the development of an oral drug candidate for the upcoming phase 1 study. This means that the planned start of the first study in humans is revised to mid-2023. An oral drug is more convenient for patients and means that Dicot's drug candidate will be higher valued in future business negotiations with potential partners.

Elin Trampe tillträder som VD på Dicot AB

Pressmeddelande: Uppsala, 1 april 2022. Elin Trampe tillträder idag som VD för läkemedelsföretaget Dicot. Elin tar med sig viktig erfarenhet från bl.a. affärsutveckling, internationella partnerskap och operationell excellens in i VD-rollen, ett uppdrag med fokus på att ta bolaget in i nästa fas. Elin Trampe ersätter Göran Beijer som kvarstår som konsult i bolaget.

Elin Trampe takes over as CEO of Dicot AB

Press release: Uppsala, April 1, 2022. Elin Trampe is the new CEO of the pharmaceutical company Dicot starting today. Elin brings important experiences from e.g. business development, international partnerships and operational excellence. Elin's focus as new CEO will be to focus on taking the company into the next phase. Elin Trampe succeeds Göran Beijer, who remains in the company as a consultant.

Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted